文献速递生殖医学

附睾异常而非睾丸异常与抗精子抗体发生相关:基于MAR试验的评估

Epididymal more than testicular abnormalities are associated with the occurrence of antisperm antibodies as evaluated by the MAR test.
PubMed 文献 · Hum Reprod · 2018-01-01

该横断面分析纳入109名不育夫妇男性和699名不育夫妇中连续就诊男性,其中181名不育男性和109名生育男性MAR试验可评估。MAR试验阳性在不育男性中更常见(11% vs 3.7%,P<0.05),且与附睾超声异常、附睾炎病史及高sIL-8水平相关,而与精液常规参数无关。

要点

  • 不育男性MAR试验阳性率11%,生育男性3.7%,不育组更高(P<0.05)。
  • MAR试验阳性与附睾体尾部平均大小及附睾回声质地异常相关。
  • MAR试验阳性者更常有附睾炎病史和高sIL-8水平,与精液参数无关。

核心结论

  • MAR试验阳性与提示慢性附睾炎症的临床和超声特征相关,而非睾丸损伤。
  • MAR试验阳性在不育夫妇男性中比生育男性更常见,但与常规精液参数值无关。
  • 作者认为数据支持抗精子抗体在不育夫妇中的作用, regardless of conventional sperm analysis,其影响夫妇生育的机制需进一步研究。

研究设计与样本

  • 横断面分析,纳入109名生育男性和699名2012年9月至2017年9月因夫妇不育连续就诊的男性。
  • 699名不育男性中181名(年龄38.6±6.6岁)MAR试验可评估,109名生育男性(年龄36.6±5.2岁)全部可评估。
  • 所有受试者在同一天于门诊完成体格、内分泌、阴囊和经直肠超声评估及精液分析(包括sIL-8)。
  • 关联分析在290名男性(不育男性+生育男性)的总样本及不育和生育两个队列中分别进行。

主要发现

  • 181名不育男性中20名(11%)MAR试验阳性,其中12名(6.6%)MAR试验≥50%(WHO认定的病理阈值)。
  • 109名生育男性中4名(3.7%)MAR试验阳性,其中1名(0.9%)MAR试验≥50%。
  • 不育男性MAR试验阳性率高于生育男性(P<0.05)。
  • 在290名男性总样本中,MAR试验阳性与精液特征无相关性。
  • MAR试验阳性与附睾超声异常相关,尤其是附睾体和尾的平均大小(均P<0.0001);在不育男性中,MAR试验阳性还与附睾回声质地异常相关。

关键数值与推荐

  • MAR试验≥50%被视为病理阈值(根据WHO)。
  • 不育男性MAR试验阳性率11%(20/181)vs 生育男性3.7%(4/109),不育组更高(P<0.05)。
  • 不育男性MAR试验≥50%者6.6%(12/181)vs 生育男性0.9%(1/109)。
  • MAR试验阳性与附睾体平均大小和附睾尾平均大小相关(均P<0.0001)。
  • MAR试验阳性与LH水平的校正相关系数adj. r=0.232(P<0.0001)。

临床怎么用

  • 作者指出,当评估MAR试验阳性的受试者时,应评估附睾而不仅仅是睾丸。
  • 作者认为MAR试验阳性在不育夫妇男性中更常见,但与常规精液参数值无关,数据支持抗精子抗体在不育夫妇中的作用。
  • 抗精子抗体如何影响夫妇生育需进一步研究。

局限性

  • 本研究使用SpermMAR试验IgG检测抗精子抗体,但其他检测方法也可用。
  • 由于技术原因,严重少弱畸精子症受试者无法评估MAR试验,因此该检测可能导致内在选择偏倚。
  • 由于研究的横断面性质,无法推断因果关系假设或机制模型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is there any association between mixed antiglobulin reaction (MAR) test positivity and clinical features or genital tract ultrasound (US) parameter values in males of infertile and fertile couples? STUDY ANSWER: In males of infertile and fertile couples MAR test positivity was associated with clinical and US features suggestive of chronic epididymal inflammation. WHAT IS KNOWN ALREADY: MAR test positivity has been more often reported in males of infertile couples than in fertile men. A positive MAR test has been detected in men with a history of testicular or post-testicular damage. No previous study has reported US alterations related to MAR test positivity. This is the first study that has systematically evaluated associations between a positive MAR test and clinical, seminal and US characteristics of the entire male genital tract. STUDY DESIGN, SIZE, DURATION: This cross-sectional analysis included 109 fertile men and 699 consecutive subjects seeking medical care for couple infertility from September 2012 to September 2017. PARTICIPANTS/MATERIALS, SETTING, METHODS: All subjects underwent, in our outpatient clinic, a complete physical, endocrine, scrotal and transrectal US evaluation and semen analysis (including sIL-8) on the same day. Of the 699 males of infertile couples, 181 (age 38.6 ± 6.6 years) had an assessable MAR test, whereas the test was assessable in all 109 fertile men (age 36.6 ± 5.2 years). The associations among MAR test positivity and the other studied parameters were investigated on a caseload of 290 men (patients + fertile men) and in the two cohorts of males of infertile and fertile couples. MAIN RESULTS AND THE ROLE OF CHANCE: Of the 181 men of infertile couples studied, 20 (11%) had a positive MAR test, including 12 (6.6%) who had a MAR test ≥ 50%, which is considered as a pathological threshold according to the WHO. Of the 109 fertile men, four (3.7%) had a positive MAR test, of which one (0.9%) had a MAR test ≥ 50%. MAR test positivity was therefore found more often in men of infertile couples (P < 0.05). In the entire caseload (n = 290) of males of both infertile and fertile couples, no correlations between MAR test positivity and seminal characteristics were observed. A positive MAR test was associated with epididymal US abnormalities, particularly with the mean size of the epididymal body and tail (both P < 0.0001), and in infertile men, a positive MAR test was also associated with an abnormal epididymal echotexture. In addition, subjects with a positive MAR test more frequently showed a history of epididymitis and high sIL-8 levels. Considering endocrine parameters, only a positive correlation between MAR test positivity and LH levels was observed, even after adjusting for age and life-style factors (adj. r = 0.232, P < 0.0001), while no associations with testosterone and FSH levels were found. LIMITATIONS, REASONS FOR CAUTION: Antisperm antibodies (ASA) were detected in this study by using the SpermMAR test IgG, but other tests are available. In addition, for technical reasons, the MAR test is not assessable in subjects with severe oligo-astheno-zoospermia and, therefore, this test may lead to an intrinsic selection bias. Finally, owing to the cross-sectional nature of the study, neither a causality hypothesis nor mechanistic models can be inferred. WIDER IMPLICATIONS OF THE FINDINGS: First, our results indicate that MAR test positivity is associated with clinical and US signs suggestive of chronic epididymal inflammation and not testicular damage. Hence, when investigating a subject with a positive MAR test, the epididymis and not just the testis should be evaluated. Furthermore, MAR test positivity was more often detected in males of infertile couples than in fertile men, but it was not associated with conventional semen parameter values. Our data support a role of ASA in couple infertility, regardless of the conventional sperm analysis. How ASA affects couple fertility needs to be addressed by further studies. STUDY FUNDING/COMPETING INTEREST(S): Grants were received from the Ministry of University and Scientific Research (SIR project to F.L., protocol number: RBSI14LFMQ). There are no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Lotti F, Baldi E, Corona G, et al. Epididymal more than testicular abnormalities are associated with the occurrence of antisperm antibodies as evaluated by the MAR test. Hum Reprod. 2018. PMID: 29982596. doi:10.1093/humrep/dey235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。